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Bacterial and viral upper respiratory infections (URI) produce highly variable clinical symptoms that cannot be used to identify
the etiologic agent. Proper treatment, however, depends on correct identification of the pathogen involved as antibiotics
provide little or no benefit with viral infections. Here we describe a rapid and sensitive genotyping assay and microarray for
URI identification using standard amplification and hybridization techniques, with electrochemical detection (ECD) on
a semiconductor-based oligonucleotide microarray. The assay was developed to detect four bacterial pathogens (Bordetella
pertussis, Streptococcus pyogenes, Chlamydia pneumoniae and Mycoplasma pneumoniae) and 9 viral pathogens (adenovirus
4, coronavirus OC43, 229E and HK, influenza A and B, parainfluinza types 1, 2, and 3 and respiratory syncytial virus. This new
platform forms the basis for a fully automated diagnostics system that is very flexible and can be customized to suit different
or additional pathogens. Multiple probes on a flexible platform allow one to test probes empirically and then select highly
reactive probes for further iterative evaluation. Because ECD uses an enzymatic reaction to create electrical signals that can be
read directly from the array, there is no need for image analysis or for expensive and delicate optical scanning equipment. We
show assay sensitivity and specificity that are excellent for a multiplexed format.
Citation: Lodes MJ, Suciu D, Wilmoth JL, Ross M, Munro S, et al (2007) Identification of Upper Respiratory Tract Pathogens Using Electrochemical
Detection on an Oligonucleotide Microarray. PLoS ONE 2(9): e924. doi:10.1371/journal.pone.0000924
INTRODUCTION
Upperrespiratorytractinfections(URI)canbecausedbyavarietyof
viruses, including rhinovirus, coronavirus, influenza A and B,
parainfluenza, respiratory syncytial virus, adenovirus, metapneumo-
virus, and enterovirus; and by bacteria, including Chlamydia
pneumoniae, Mycoplasma pneumoniae, Streptococcus pyogenes, S. pneumoniae,
Bordetella pertussis,and Haemophilus influenzae[1,2,3].Clinicalsymptoms
of URI are highly variable and cannot be used to identify the
etiologic agent or agents. Although the majority of URI are caused
by viruses (69%; [3]), antibiotics are widely prescribed to treat
symptoms. Antibiotics, which are of little or no benefit for viral
infections, can contribute to the emergence and spread of resistant
bacteria and to higher costs for health care [4,5,6].
The rapid identification of certain viruses and bacteria is
necessary for proper treatment of infection. Patients with a history
of rheumatic fever (Streptococcus), patients with bacterial or viral
infections for which specific therapies are available, and patients
whose URI symptoms persist for over two weeks, can benefit from
rapid detection. Rapid and accurate identification of URI agents
at the point of care can reduce the inappropriate prescription of
antibiotics and help identify problematic infections early.
Traditional methods for the identification of URI pathogens,
including culture and serology, are effective but are labor intensive
and may require highly trained personnel and days to weeks to
complete. Many rapid serological tests are not sensitive or specific
enough to detect all infections. Enzyme immunoassays (EIA)
generally show sensitivities of 85% and direct immunofluorescence
(DIF) assays show sensitivities of approximately 60 to 80% [7].
Although viral culture is generally accepted as the gold standard
for diagnosis, PCR can be more sensitive [8]. In one study,
rhinovirus culture detected infection in 40% of patients while
rhinovirus PCR detected infection in 51.5% of patients [3].
Similarly, an influenza virus surveillance study showed that 18% of
samples were positive by culture and 28% were positive by
TaqMan-PCR [9].
Because of their speed, specificity and sensitivity, genomic assays
are complementary to serological assays and especially useful for
identifying an unknown specimen where antibodies are not
specific enough to differentiate closely related groups [10,11,12,13,
14,15,16,17,18,19,20,21,22]. Reverse transcription-polymerase
chain reaction (RT-PCR) is widely used for identifying virus and
bacteria; however, a positive amplification is often verified by
subsequent procedures that provide sequence information
[8,23,24]. By using multiple probes against a single pathogen
coupled with the proper amplification scheme, microarrays can
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and sequencing [13,14,21,25,26,27,28,29,30,31,32,33].
While traditional assays for pathogen detection and typing
represent the gold standard, they alone, cannot meet the future
needs for rapid, sensitive, specific and simple methods. The
majority of these approaches do not provide sequence informa-
tion, utilize expensive equipment that cannot be easily transported,
require a high level of expertise to operate equipment, require
extended periods of time, or are not easily modified. Here we
describe a rapid and sensitive genotyping assay and array for
upper respiratory pathogen identification using standard amplifi-
cation and hybridization techniques and electrochemical detection
(ECD) on a semiconductor-based oligonucleotide microarray. This
platform was particularly suitable for developing this assay because
it supports custom probe synthesis, which permits oligonucleotides
of interest to be tested empirically. Multiple, highly reactive probes
that are specific for a particular organism can then be put on the
array for further iterative evaluation. Content of the final assay can
also be customized to suit diagnostic needs in different geographic
areas. Finally, the ability to use electrochemical detection with
semiconductor microchips eliminates the need for expensive and
delicate optical scanning equipment [34,35,36]. Scanning of
microarrays is typically labor intensive and a significant source
of system noise that complicates the use of microarrays signifi-
cantly; and has hampered the transition of these technologies into
high throughput clinical scenarios by adding undue instrumenta-
tion cost and complexity. The ECD method of deriving signal
from a microarray is extremely simple and provides a clear path to
making microarray processing truly hands off throughout the
entire process.
RESULTS
URI pathogen genotyping assay
The assay was designed to identify 10 upper respiratory pathogens,
with subtype identification in some cases (coronavirus and
parainfluenza virus). We utilized multiple probes for each
pathogen (approximately 30 to 100) that were designed from
conserved regions of the respective genomes. Approximately 850
unique URI probes were included on the array with 12 to 13
replicates for each probe. The assumption for this methodology is
that enough unique probes will produce specific signal in the
presence of the labeled PCR products to result in a positive call.
Multiple probes allow for genetic variability, especially with viral
genomes, and also provide sequence information. In principle it is
straightforward to substitute other organisms in these assays by
synthesizing arrays with alternate probe specificity and alternate
primer sets.
Amplification and labeling
One-tube RT-PCR was used for target amplification and labeling
because of its sensitivity and its application to both DNA and RNA
targets (Fig. 1). Our PCR primers flanked conserved regions that
had complementary sequences to the probes on the array. The
combination of microarrays with RT-PCR allowed for the
detection of specific signal from a complex reaction mix containing
background NA. The PCR amplification/labeling reactions took
approximately 3.5 hrs with a peltier thermal cycler; however the
reaction time was reduced to less than two hours using a Light-
Cycler (Roche). Single-strand target was produced by adjusting the
melting temperature of the forward and reverse primer pools to
approximately 50uC and 65uC respectively. This 15uC tempera-
ture differential between primer sets allowed for a 50uC reverse
transcription step followed by exponential amplification at 56uC.
Increasing the annealing temperature of the reaction to 68uC, with
30 additional rounds of amplification, resulted in a predominantly
one-way reaction favoring reverse primer extension. Biotin
labeling occurred during amplification by incorporation of
biotinylated dCTP/dATP in the reaction mix. Biotinylated reverse
primers were also employed as an alternate method for biotin
labeling.
We compared the sensitivity and specificity of biotin labeling by
incorporation during amplification versus biotinylated reverse
primers (Fig. 2). Although using biotinylated reverse primers
increased assay sensitivity, nonspecific signal increased due to
binding of free biotinylated oligonucleotides to specific probes.
This background could be eliminated during analysis by removing
approximately 2% of the high and low signal for each genotype
category prior to averaging.
Hybridization and electrochemical detection
While the microarray can be used with fluorescence detection, we
used electrochemical detection (ECD), which relies on a redox
reaction to generate electrical current (pA) on the array for
measurement. Pseudo-images of two hybridized targets are shown
in Figure 3A (M. pneumoniae) and B (coronavirus 229E). These
images are a representation of hybridization signals (i.e. current)
derived from the raw data. This is in contrast to conventional
microarray technology where the data are derived from the image
and subsequently analyzed. Signal is predominately seen in the
respective block of specific probes for each organism with scattered
Figure 1. Strategy for amplification and labeling of pathogen-specific
target. The one-tube RT-PCR reaction includes three stages: A) Reverse
transcription reaction to produce first strand cDNA for viral targets
(vRNA); B) Low temperature (56uC), exponential amplification of target
and C) High temperature (68uC), linear amplification to product single-
strand, biotin-labeled target. Target is labeled by incorporation of
biotin-14-dCTP during amplification or by the use of biotinylated
reverse primers.
doi:10.1371/journal.pone.0000924.g001
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specific block of probes resulted from: 1) variable biotin labeling
due to amplicon size and GC content; 2) variation in probe-target
interaction due to genomic variability; and 3) predictable and un-
predictable nucleotide base-pairing characteristics of probes. To
overcome these issues, we determined a specific genotype based on
the average signal intensity of all pathogen-specific probes, which
includes 12 to 13 replicates of each probe. This was done rapidly
using an Excel macro to generate bar graphs to identify the most
likely candidate(s).
URI assay validation
Results of array validation studies are shown in Figure 4. The
prototype URI array contained probes representing two to six
amplicons per organism (see Table 1) and two primer pools
consisting of 18 primer pairs for RNA targets and 19 primer pairs
for DNA targets (pools 1A and 2A respectively). Both pools
contained two primer pairs for the Arabidopsis positive control
(Cont.) spike-in nucleic acids for both DNA and RNA genome
targets (spike-ins were predominately used for unknown samples
and not for validation). Assays were designed to genotype each of
the 10 URI pathogens with coronaviruses and parainfluenza
viruses subdivided into three subtypes. Each of the 10 target
genomes was successfully identified with little or no background
cross-reactivity (Figs 4A and B).
Primer pool optimization
Initial studies were conducted with two primer pools consisting
of 19 primer pairs for DNA targets and 18 primer pairs for
RNA targets (Pools 1A and 2A; Table 1). Subsequent studies
to determine primer interactions and optimal target signals on
the array resulted in reducing primer pool sizes to increase
assay sensitivity (Fig. 5). Primer pool 1B for DNA targets
included 10 of the original primer pairs and pool 2B for RNA
included 9 of the original primer pairs. A third primer pool for
DNA targets, pool 1C, contained only 5 primer pairs (see
Table 1). A comparison of DNA target primer pools A, B, and
C, shown in Fig. 5, demonstrates the increased sensitivity of
pools 1B and 1C over pool 1A in detecting increasing dilutions
M. pneumoniae DNA. All pools produced sufficient PCR
products for detection on arrays at a 1:1,000 dilution of target
DNA (1 pg). Pools B and C were effective on samples diluted
1:10,000; but only pool C was effective at dilutions above
1:10,000.
Primers for assay positive control A. thaliana RNA and DNA
RT-PCR reaction spike-ins, originally consisted of three primer
pairs: 1) A. thaliana RCA gene primers for DNA targets, 2) A.
thaliana Cab gene primers for RNA targets, and 3) A.thaliana rcbL
gene primers for both DNA and RNA targets. The primer set for
the rcbL gene was subsequently removed from the final assay to
improve performance.
Figure 2. Comparison of assay sensitivity with target labeled by biotin-incorporation and biotinylated primers. B. pertussis (B.pert, arrow)
genomic DNA at 15 ng/ul was diluted to 1:1,000 (top panels) and 1:10,000 (bottom panels) and labeled either by biotin-incorporation (left panels) or
with biotinylated reverse primers (right panels). The average of type-specific probe group signals in picoamps is shown at the left and identity of
pathogen type-specific probe groups is shown below panels. The horizontal bar indicates the assay cutoff, which was determined by the mean value
of negative control probes plus 3 standard deviations of the mean.
doi:10.1371/journal.pone.0000924.g002
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Using optimized primer pools (1C and 2B) and probe sequences,
sensitivity studies were conducted on 10-fold serial dilutions of NA
from each target organism. Starting NA concentrations were
determined spectrophotometrically and from vendor specifications
(Table 2). Exact concentrations of specific target organism NA was
probably less because of host cell NA contamination and loss of
material during NA isolation. In addition, when NA concentra-
tions were based on PFU/CFU, the contribution of non-viable
organism NA could not be determined. The URI genotyping assay
could detect NA dilutions to approximately 1 to 10 genomes for 9
of 12 target categories (Table 2 and Figure 6). Less sensitivity was
achieved for Bordetella pertussis and parainfluenza (PIV) types 1 and
3. The URI genotyping assay was also tested by including NA
from the 5 organisms with DNA genomes and the 5 organisms
with RNA genomes in separate PCR reactions, and then
combining reactions for hybridization to arrays (Fig. 7). This did
not result in the loss of a specific pathogen signal for the dilutions
tested.
Signal specificity was determined by comparison of specific
target signal to negative control probe signal and to signal from
non-target probes. As shown in Figure 4A and B, very low signal
(background) was seen on probes that were not specifically
targeted. Probes for coronavirus and PIV represented three
subtypes of each virus: coronavirus 229E, HK, and OC43; and
PIV types 1, 2, and 3. When one subgroup was targeted, little
signal was seen on probes for the other two subgroups as shown in
Figures 6B, 6D and 7.
DISCUSSION
A variety of multiplexed assays for the identification of mixed
targets have been reported that use electrophoresis, molecular
beacons, or enzymatic assays for detection [8,37,38]. Solid-phase
PCR on microarrays has also been used for genotyping assays
[39,40]. This approach allows for either specific array probe
extension and labeling for genome identification or on-chip
isothermal, strand-displacement amplification. An assay combin-
ing a multiplexed RT-PCR platform with a library of photo-
Figure 3. Pseudoimage of raw data from scanned chips illustrating Mycoplasma pneumoniae (A) and coronavirus 229E (B) detection. The left
panels (Probe Map) show the position of all pathogen-specific probes and include 3 sub-type probes for coronavirus and parainfluenza virus.
Geometric shapes indicated by arrows are areas on the microarray dedicated to array quality control probes. Positive control target was included only
with M. pneumoniae (A). Coronavirus probes are divided into three sections on the array: 1) Type 1, 2) Type 2, and 3) Type 3.
doi:10.1371/journal.pone.0000924.g003
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has been used to identify 22 respiratory pathogens [41]. Lin and
colleagues [42] have used multiplexed RT-PCR combined with
resequencing microarrays to identify multiple respiratory tract
pathogens in a 12-hour assay. The majority of these approaches
either do not provide sequence information, utilize expensive
equipment that cannot be easily transported, require a high level
of expertise to operate equipment or are not easily modified for
additional pathogens.
In this study, we describe a rapid and sensitive genotyping assay
for URI. This genotyping assay uses the same protocol to detect
both bacteria and viruses that produce upper respiratory clinical
symptoms; and it relies on the simultaneous examination of
numerous loci to differentiate one organism from another.
Microarray technologies can provide a significant amount of
information at disparate loci in a highly redundant fashion that is
helpful when discriminating between similar or different organisms
or compensate for cases where genomic variation can result in
false negative signals. In this array design, probes were developed
to be species and sub-species-specific and then crosschecked
against databases to minimize the possibility of cross-hybridization
of target with other probes or with contaminating host NA.
Multiple probes per pathogen (approximately 30 to 100) were used
to overcome potential variability in pathogen genomes and also to
provide sequence information at disparate loci. PCR primers were
designed to flank the conserved regions that contained multiple
complementary probe sequences. They also were designed such
that the one-tube RT-PCR reaction produced biotin-labeled,
single-strand target for hybridization to arrays. Decreasing the
number of primer pairs per multiplex RT-PCR also increased
assay sensitivity. Greatest sensitivity was achieved with one primer
pair per genome of interest.
Equal labeling for GC-rich and AT-rich genomes was promoted
by including both biotin-dCTP and biotin-dATP in PCR
reactions. This is especially relevant for B. pertussis with a genome
GC content of 67% and RSV with a GC content of 33%. Greater
assay sensitivity was obtained by using 59 biotinylated reverse
primers in place of biotin-dCTP incorporation during amplifica-
Figure 4. URI chip validation studies showing average RNA genome (A) and DNA genome (B) target signal intensity for the 10 upper respiratory
pathogens studied. The left panels (GENOTYPE) show the average genotype-specific probe signal in picoamps that is used to determine a genome
identity. The right panels (PROBES) illustrate the average probe signal intensities of 12 replicates for each probe and also illustrate signal specificity for
both positive and negative probes. Pathogens are ADV (adenovirus 4), B.p.( Bordetella pertussis), C.p.( Chlamydia pneumoniae), CV (coronavirus), InfA
(influenza A), InfB (influenza B), M.p.( Mycoplasma pneumoniae), PIV (parainfluenza virus), RSV (respiratory syncytial virus), and S.p.( Streptococcus
pyogenes) at nucleic acid concentrations described in Table 2.
doi:10.1371/journal.pone.0000924.g004
Respiratory Pathogen Array
PLoS ONE | www.plosone.org 5 September 2007 | Issue 9 | e924tion, as biotin-dCTP inhibits the PCR reactions (data not shown).
However, with this increase in sensitivity, we also observed
a slightly higher background signal and also a specific pattern of
binding of free biotinylated primers to some probes. Removing
microarray probes that bind to the free biotinylated primers can
reduce this background artifact.
The arrays were validated by hybridizing labeled target that was
generated from RNA or DNA from all viruses and bacteria
represented on the upper respiratory chip, which includes
influenza A and B; parainfluenza types 1, 2, and 3; adenovirus
4; respiratory syncytial virus; coronavirus 229E, HK, and OC43;
Streptococcus pyogenes; Bordetella pertussis; Chlamydia pneumoniae; and
Mycoplasma pneumonia. The arrays contain multiple probes per
amplified region and multiple regions per organism that
correspond to key distinguishing elements of each organism or
subtype. However, to increase assay sensitivity, the final primer
Table 1. Primer pools, amplicons and probes for the URI assay.
..................................................................................................................................................
Pool Target Forward Reverse Gene Amplicon A B C Probes
1 B. pertussis Bp_For_1 Bp_Rev_1 LysR TR 427 * 8
1 " Bp_For_2 Bp_Rev_2 ABC T 476 ***1 8
1 " Bp_For_3 Bp_Rev_3 ADH 769 * 14
1 " Bp_For_4 Bp_Rev_4 LysR TR 569 * 21
1 " Bp_For_5 Bp_Rev_5 tfdA 552 * 10
1 " Bp_For_6 Bp_Rev_6 CAIB 534 * * 15
1 M. pneumoniae Mp_For_1 Mp_Rev_1 dnaK 564 * 29
1 " Mp_For_2 Mp_Rev_2 pdhA 284 ***1 8
1 " Mp_For_3 Mp_Rev_3 tuf 604 * * 33
1 S. pyogenes Sp_For_1 Sp_Rev_1 3-oxoacyl 510 * 19
1 " Sp_For_2 Sp_Rev_2 23S rRNA 463 * * 26
1 " Sp_For_3 Sp_Rev_3 ABC T 421 ***2 4
1 C. pneumoniae Cp_For_1 Cp_Rev_1 clp endop 491 * 23
1 " Cp_For_2 Cp_Rev_2 HB-2 528 ***2 5
1 " Cp_For_3 Cp_Rev_3 29 kDa lip 475 * 23
1 " Cp_For_4 Cp_Rev_4 RNA pol S 526 * 22
1 " Cp_For_5 Cp_Rev_5 R-Isomer 526 * * 20
1 Adenovirus 4 Adv_For_1 Adv_Rev_1 gp 12 531 * * 55
1 " Adv_For_2 Adv_Rev_2 gp 12 606 **** *
2 Coronavirus 229E CV229E_F_1 CV229E_R_1 Matrix 299 * * 20
2 Coronavirus HK CV HK_F_1 CV HK_R_1 HE 767 * * 22
2 Coronavirus OC43 CVOC43_F_1 CVOC43_R_1 HE 528 * 28
2 " CVOC43_F_2 CVOC43_R_2 N 507 * * 33
2 Influenza A InfA_For_1 InfA_Rev_1 Matrix 500 * * 20
2 " InfA_For_2 InfA_Rev_2 Matrix 339 * 13
2 Influenza B InfB_For_1 InfB_Rev_1 NP 516 * * 29
2 " InfB_For_2 InfB_Rev_2 Matrix 506 * 28
2 PIV 1 PIV1_For_1 PIV1_Rev_1 Matrix 488 * * 28
2 " PIV1_For_2 PIV1_Rev_2 HN 532 * 23
2 PIV 2 PIV2_For_1 PIV2_Rev_1 Matrix 576 * 28
2 " PIV2_For_2 PIV2_Rev_2 NP 592 * * 34
2 PIV 3 PIV3_For_1 PIV3_Rev_1 Matrix 840 * * 35
2 " PIV3_For_2 PIV3_Rev_2 HA 517 * 24
2 RSV RSV_For_1 RSV_Rev_1 Matrix 2 440 * 18
2 " RSV_For_2 RSV_Rev_2 Matrix 2 496 * 22
2 " RSV_For_3 RSV_Rev_3 Phos 412 * 23
2 " RSV_For_4 RSV_Rev_4 Fusion 474 * * 18
Cont. Arabidopsis RCA For RCA Rev RCA 508 ***3 2
Cont. " Cab For Cab Rev caB 501 ***2 3
Cont. " rbcL For rbcL Rev rcbL 515 * 12
*Primer pair included in the respective sub-pool.
**Probes used for both amplicon 1 and 2.
doi:10.1371/journal.pone.0000924.t001
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PLoS ONE | www.plosone.org 6 September 2007 | Issue 9 | e924Figure 5. Comparison of assay sensitivity with primer pools 1A, 1B, and 1C. Mycoplasma pneumoniae (M.p.) DNA, at 1 ng/ul, was serially diluted
and amplified with primer pools 1A (3 M.p. amplicons), 1B (2 M.p. amplicons), and 1C (1 M.p. amplicon). Panels in (A) illustrate the sensitivity obtained
with the 3 pools at M.p. DNA dilutions of 1:1,000 (left) and 1:10,000 (right). Average signal intensities in picoamps for each set of amplicon probes
(vertical bars) are shown at the left. The horizontal bar within graphs indicates the assay cutoff (mean 36SDM). The PCR amplicons analyzed for each
pathogen are listed in panel (B) and the three M.p. amplicons are indicated by thick underline.
doi:10.1371/journal.pone.0000924.g005
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PLoS ONE | www.plosone.org 7 September 2007 | Issue 9 | e924Figure 6. Results of sensitivity studies for Mycoplasma pneumoniae (A); coronavirus 229E (B); influenza B (C); and PIV 1, and RSV (D). Vertical
bars indicate the mean signal intensities in picoamps for positive genotypes (above cutoff bar) and negative genotypes (below cutoff bar). Horizontal
bars indicate the assay cutoff, which is based on the mean of the negative control probes, plus 3 standard deviations of the mean. Relative probe
electrochemical signal intensities in picoamps are shown to the left and probe identities are shown below. The identity of the pathogen tested and
the dilution factor are shown on each graph. Beginning target nucleic acid concentrations are shown in Table 2.
doi:10.1371/journal.pone.0000924.g006
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bacteria samples could be identified individually or in mixtures of
10 organisms within 5 hrs. Under optimal conditions, the assay
was also sensitive, detecting 1 to 10 genomes, in most cases; and
specific, detecting signal predominately on the pathogen probes of
interest and not on probes for closely related species or serotypes as
shown in Figures 4 through 7.
Studies to determine assay sensitivity were, in many cases,
difficult to analyze because of complexities in quantifying target
nucleic acid in a mixture with host nucleic acid. Most of the stock
target bacterial DNA and viral RNA concentrations used in this
study were based on PFU/CFU estimates provided by ATCC.
Virus PFU were determined from cell culture lysates that would
contain host cell nucleic acid. Given that one human cell contains
approximately 7 pg of DNA, host cell nucleic acid contamination
of samples could be very high. Thus, final results of assay
sensitivity, based on PFU, could be underestimated in some cases.
In this paper, we demonstrate the usefulness of ECD and
microchips as a diagnostic platform for genotyping URI. In
addition, this type of microarray can easily be subdivided into
multiple sub-arrays; e.g., 4 sectors of 2240 electrode features per
array, which allows multiple assays on one array and provides
significant cost savings. Also, because of the platform’s flexibility,
the array content and primer pools can easily be changed to reflect
the needs of clinicians in different localities and different seasons.
The high manufacturability of semiconductors and their adapt-
ability to inexpensive electrochemical microarray readers, which
are small and field deployable, make these assays much more
powerful than simple Real Time-PCR systems. In essence, the
array provides a much higher level of confidence in a result akin to
DNA sequencing; and, in addition, upfront bioinformatics and
judicious choice of probes and loci allow a greatly simplified and
speedier analysis of complex organisms or mixtures thereof.
Ghindilis et al. [35] have described electrochemical detection and
the application of this technology on the CombiMatrix array
platform. This platform is able to provide very similar sensitivity
and reproducibility to state of the art fluorescent detection. Their
analysis of data correlation between the electrochemical detection
and standard fluorescent detection techniques demonstrated that
the array-to-array correlation for both detection techniques is very
high with an average correlation coefficient of 0.94 [35].
The use of multiplexed RT-PCR combined with electrochemical
detection on micro-arrays, as described here, has several
advantages over traditional assays, including RT-PCR alone: 1)
The ElectraSenseH ECD scanner is small, portable, and rugged
and can easily be automated or incorporated as a ‘‘sub-system’’ into
other genomic analysis systems; 2) The ECD scanner is faster,
easier to use, and less expensive than fluorescence scanners; 3)
Multiplexing is simpler because the array sorts out multiple signals
that can arise from miss-priming in complex samples; 4) There is no
need to sequence PCR products because the binding of multiple
probes to specific targets provides sequence-like information; 5)
This format is flexible, allowing for multiple probes, selection of the
most reactive probes through iterative tests, and thus increased
probability of making correct calls at low target concentrations and
with rare isolates/subtypes. This platform also allows one to easily
include the detection of single nucleotide polymorphisms and short
stretches of sequence within an assay; and 6) A lowlevel of technical
expertise is needed to run assays and analyze data.
Disadvantages to using PCR for amplification are the possibility
of contaminating reactions with amplicons from previous assays
and amplifying genetic material from potential pathogens that are
part of the normal flora. We are addressing amplicon contami-
nation by developing a cartridge format for amplification, labeling,
and hybridization of target. This cartridge contains the amplicons
and is disposed of after analysis [36]. With respect to amplifying
genetic material from pathogens that are part of the normal flora,
PCR amplification is highly sensitive and is only qualitative at best.
Therefore, the assay may (as with any standard bacteriological test)
report the presence of pathogens in the absence of establishing
a direct correlation with disease. As reported by Konno et al. [42],
the flora of a healthy individual can contain pathogenic species
(e.g., S. pyogenes, S. pneumoniae, H. influenzae and Moraxella catarrhalis).
They detected these organisms in a group of healthy 0 to 6 year
olds at approximately the same rate as in patients with acute upper
respiratory infections. These organisms were also found in older
Table 2. Assay sensitivity tests for viral and bacterial URI pathogens.
..................................................................................................................................................
Sample PFU-CFU/Reaction Conc. ng/ul Highest Dilution Genomes Detected
a DNA-
b RNA/Rx
Adenovirus 4 4,375
a 90 1:10,000 1 10.0 pg
B. pertussis 4,287,000 15 1:10,000 429 3.0 pg
C. pneumoniae 438
a 116 1:100,000 1 2.3 pg
Coronavirus 229E 4,375
a 128 1:10,000,000 1 25.6 fg
Coronavirus HK -
c -- - -
Coronavirus OC43 43,750
a 760 1:10,000 5 152 pg
Influenza A ? 4.7 1:100,000 (1) 90 fg
Influenza B 43,750
a 44.7 1:1,000,000 1 89 fg
M. pneumoniae 1,393,322 1 1:1,000,000 1 2 fg
Parainfluenza Type 1 4,375,000
a 512 1:100,000 44 10 pg
Parainfluenza Type 2 - - - - -
Parainfluenza Type 3 43,750,000
a 40 1:100,000 438 800 fg
Resp. Syncytial virus 4,375
a 37 1:100,000 1 740 fg
S. pyogenes 9,775,345 16 1:1,000,000 10 32 fg
aBased on culture titers provided by ATCC.
bBased on nucleic acid concentrations.
cNot tested (included for specificity).
doi:10.1371/journal.pone.0000924.t002
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PLoS ONE | www.plosone.org 9 September 2007 | Issue 9 | e924Figure 7. Example of sensitivity and specificity tests for multiple-organism assays. Ten genotypes of interest (adenovirus 4, B. pertussis, C.
pneumoniae, coronavirus 229E, influenza A, influenza B, M. pneumoniae, parainfluenza Type 1, respiratory syncytial virus, and S. pyogenes) were
simultaneous amplified in two PCR reactions (5 DNA and 5 RNA targets) that were combined and hybridized on the same chip. Assays were run with
pathogen nucleic acid dilutions of: (A) 1 to 20 (1:20), (B) 1 to 200 (1:200), and (C) 1 to 2,000 (1:2000) that were based on the sample concentrations
listed in Table 2. Vertical bars indicate average genotype probe signals in picoamps and horizontal bars indicate the assay cutoff (mean of negative
control probes plus three standard deviations of the mean). Asterisks indicate the 10 target genomes that were amplified.
doi:10.1371/journal.pone.0000924.g007
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they were also recovered at a higher rate in smokers than
nonsmokers [44]. Clinicians must therefore verify the results of
highly sensitive assays with patient symptoms that would suggest
a bacterial infection. The inclusion of bacterial genetic markers for
antibiotic resistance or virulence in microarray assays would also
help guide the clinician in establishing an accurate diagnosis and
appropriate treatment regimen.
Rapid identification of upper respiratory pathogens will
significantly decrease the time and cost for the identification of
potential lethal virus and bacterial strains and lead to better
treatment and management of infections. Microarray and bio-
sensor technologies show great promise for virus and bacteria
detection and genotyping and are needed for rapid effective
treatment, environmental monitoring and the detection of
bioterrorism agents [22,29]. Advances in microarray processing
and simpler detection described here provide a path to migration
of microarray technologies to clinical applications.
MATERIALS AND METHODS
Viral and bacterial samples
Viral and bacterial samples were obtained from ATCC either as
cultures (Influenza B: VR-823, PIV-1: VR-94, PIV-3: VR-93,
Coronavirus OC43: VR-1558, Coronavirus 229E: VR-740, RSV-
B: VR-1580, Adenovirus 4: VR-1572, and Chlamydia pneumoniae:
VR-1355) or genomic DNA (Mycoplasma pneumoniae: 15531D). Dr.
Wanda Lyon provided nucleic acid (NA) for additional samples,
including Influenza A, Bordetella pertussis, and Streptococcus pyogenes.
Viral RNA was extracted from clinical samples and archived
cultures with an RNAeasy kit (Qiagen, Chatsworth, CA) or from
active cultures (ATCC, Manassas, VA) with Trizol (Invitrogen,
Carlsbad, CA) following the manufacturer’s protocol and pre-
cipitated with ethanol and sodium acetate (Sigma, St. Louis, MO)
in the presence of yeast tRNA (Invitrogen) and glycogen (Ambion,
Foster City, CA). Genomic DNA from bacterial cultures was
isolated with Qiagen DNeasy columns. Chlamydia pneumoniae DNA
was isolated by resuspending the culture pellet in 475 ml Tris-
EDTA, adding 25 ml 10% SDS (Sigma) and 2 ml or 20 mg/ml
proteinase K (New England Biolabs, Beverly, MA) and incubating
over night at 37uC. After heat inactivation at 70uC for 20 min,
DNA was extracted once with phenyl/chloroform/isoamyl alcohol
(25:24:1; Sigma), twice with chloroform (Sigma), and precipitated
with 3M sodium acetate and ethanol. Concentrations of RNA and
DNA were measured with a NanoDrop ND-1000 Spectropho-
tometer (NanoDrop Technologies, Wilmington, DE). Positive
control Arabidopsis DNA (RCA at 1 ng/ml) and RNA (CAP at
1 ng/ml) for RT-PCR reaction verification was obtained from
Invitrogen (SpotReport-3 Array Validation System). Positive
control RNA and DNA were diluted (1:20) in a solution of 20 ml
yeast tRNA (1 mg/ml; Invitrogen) and 4.8 ml BSA (10 mg/ml;
New England Biolabs) in 475.2 ml 10 mM Tris pH 7.4 (dilution
buffer) (Sigma).
Microarray, probe and primer design
Microarrays used in this study were ElectraSenseH 12K micro-
arrays (CombiMatrix Corp. Mukilteo, WA) that contain 12,544
individually addressable electrodes linked by the semiconductor
circuitry. Contact pads on the array allow for electrical
connectivity with an external device to control custom synthesis
of unique probes at each electrode, and electrochemical detection
with the ElectraSenseH microarray reader (CombiMatrix Corp).
Each electrode has a distinct DNA probe above it, and each
electrode can be read electronically or fluorescently to determine
the level of hybridization for a specific DNA sequence.
Probe and primer design was achieved by aligning URI pathogen
sequences obtained from GenBank and finding suitable regions for
amplification and detection of each organism. A context database
was then created for each organism to be typed. This was
accomplished by collecting all available genomic sequences sharing
the same genus or serotype as the sequence being investigated. Next,
a structured BLAST database was created by incorporating genus
and species information into the label of each context genomic
sequence. For each organism to be typed, the gene sequences were
extracted from the genomic record using the GenBank annotation.
These gene sequences were then searched against the context
database. All the matches between a gene of interest and a given
context database genome were parsed to reflect each gene’s
conservation within that related genome. The specificity of each
gene was reported in relation to the context database.
Genes were chosen for probe design based on their specificity
within the organism’s home clade. A combination of sub-type-
specific, species-specific as well as clade-specific genes were chosen.
The desired specificity for gene choice depended on what one
wanted to discern within the topography of the organism’s home-
clade. In general, for each organism of interest, genes were chosen
whose specificities included unique as well as conserved sequences.
If discernment was to be made between two closely related
organisms, more specific genes that would allow discrimination
were chosen. Five to ten genes were initially selected for each
organism of interest. For each gene chosen, isothermal Tm 60uC
probes were designed in half-probe-length steps across each
sequence. Only good-quality probes, as defined by convention,
were accepted. For example, probes could not contain repeat
region greater than 6 bp in length, significant secondary structure,
or GC percentage less than 35% or greater than 65%.
After design, the probes were searched against the context
database and their specificity was reported with respect to the
context database. Regions within genomes that had the desired
specificity were then selected. These regions were approximately
500 bp in length, and contained the probes that exhibited the
desired specificity. The first and last probes of each region were
designated as amplifying primers (the reverse primer was anti-
sense), and the sequences in between were used as probes on the
microarray. Where possible, PCR primers were chosen that were
conserved within the clade. The forward primers were created
with a Tm of approximately 50uC where as reverse primers were
created with a Tm of approximately 65uC. This differential in
temperature allowed for both amplification and single-strand
target production. Bacterial and viral genes used for probe and
primer selection are listed in Table 1.
Target amplification and labeling
Two methods were used for labeling NA during RT-PCR: biotin-
14-dCTP incorporation (see Fig. 1) or biotinylated reverse primers
(Integrated DNA Technologies, Coralville, IA). Twenty-five ml
reaction mixes included 12.5 ml of reaction buffer (Invitrogen;
SuperScript III One-Step RT-PCR kit with Platinum Taq), 2 mlo f
5 mM MgSO4, 0.7 ml of 0.4 mM biotin-14-dCTP (Invitrogen) or
biotin-11-dATP (PerkinElmer, Boston, MA), 2 ml primer pool
(IDT, Coralville, IA), 1 ml Arabidopsis positive control mix, 0.5 ml
enzyme mix, 2 ml RNA or DNA sample (diluted in positive control
dilution mix (see above) and 4.3 ml dH2O. Thermal cycling
parameters were: (50uC–30 min)61 cycle; (94uC–3 min)61 cycle;
(94uC–30 sec, 56uC–45 sec, 72uC–45 sec)640 cycles; (94uC–
30 sec, 68uC–60 sec)630 cycles and (72uC–5 min)61 cycle.
Amplification product was initially identified by loading 3.0 mlo f
Respiratory Pathogen Array
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staining with SYBR Green I (Molecular Probes, Invitrogen). For
ECD assay sensitivity, 10-fold serial dilutions of NA samples (10-1
to 10-8) were made in buffer containing 40.0 mg yeast tRNA
(Invitrogen) and 9.6 mg BSA (NEB) per 1.0 ml of dH2O.
PCR optimization
Each PCR reaction component, including magnesium, biotin and
primer pool concentration, was tested individually at various
concentrations. Primer pairs were tested individually with their
respective template, and each primer sequence was tested ‘‘in
silico’’ (Clone Manager Suite, Version 7.1, Scientific and
Educational Software Durham, NC) for interactions with multi-
plexed primers to eliminate cross reactivity. PCR temperatures
and dwell times were adjusted for optimal sensitivity. The
composition of primer pools was tested by varying the number
of primer sets for each target organism (see Table 1).
Microarray hybridization and electrochemical
detection
Initially, microarrays were incubated for 30 min at 45uCi n5 0ml
of a solution consisting of 5 ml of 26hybridization solution (see
below), 1 ml of 506Denhardt’s solution (Sigma) and 0.5 ml of 1%
SDS (Sigma). For hybridization (see Fig. 8), PCR reactions from
primer pools were combined and mixed 1:1 with 26hybridization
buffer, which consisted of 6 ml of 206SSPE (Ambion, Austin,
TX), 0.1 ml of 10% Tween 20 (Sigma), 0.56 ml of 0.5 M EDTA
(Ambion), 0.5 ml of 1% SDS (Sigma) and 3.84 ml of dH2O
(Ambion). Microarray hybridization chambers were filled (50 ml
volume) and sealed with tape. The arrays were incubated for 1 hr
at 45uC with rotation in a hybridization oven (Fisher Scientific,
Pittsburgh, PA) and washed for 5 min at 45uC with 36SSPE with
0.05% Tween 20; twice with 26PBS with 0.1% Tween 20 (PBST);
and then blocked for 5 min with 56PBS/Casein (BioFX Labora-
tories, Owing Mills, MD). For labeling, microarrays were incubated
for 30 min with ExtrAvidin Peroxidase (Sigma) diluted 1:1000 in
BSA Peroxidase Stabilizer (BioFX). Arrays were washed twice with
26PBST, and twice with pH4 Conductivity Buffer Substrate
(BioFX). TMB Conductivity 1 Component HRP Microwell Sub-
strate (BioFX) was added to the array, and it was scanned
immediately with an ElectraSenseH microarray reader (CombiMa-
trixCorp).ThisinstrumentmeasuresmAateachof12,544electrodes
on the array in 25 sec and outputs data in picoamps to a simple text
filethat can be used to create a pseudoimage or can be transferred to
and graphed with an Excel macro.
Data analysis
For the analysis of raw intensity data from arrays, we developed
a simple sorting and averaging algorithm in Excel. The organization
of the data was keyed to the probe name. (e.g.: Case 1) PosCntrl-
ATRCA|Probe-031; Case 2) PosCntrl-Cab|Probe-004; Case 3)
Corona-229E|Probe-019; and Case 4) Corona-HK|Probe-001).
Probe sequence information was organized and stored according to
organism type and sub-type; with the sub-type section of the probe
name occurring before the main delimiter, the bar (‘‘|’’), and the
typesectionoftheprobenameappearingbeforethedash(‘‘-‘‘),when
present. Thus the types for Cases 1 and 2 are ‘‘PosCntrl’’, and the
sub-type for Cases 3 and 4 are ‘‘Corona-229E’’ and ‘‘Corona-HK’’,
respectively. The data could be further divided into individual
amplicon-specific probes. Once broken down into their groupings,
the average signal for each type and sub-type was calculated,
presented and graphed as a simple bar graph in picoamps. For an
average signal to be considered significant, it had to be greater than
three standard deviations above the mean signal of the negative
controls. This calculation is termed the Assay Cut-off and is graphed
as a horizontal line along the bar graph for simplicity of presentation
and interpretation. Through this method of analysis, multiple
positive results may be detected in a single assay.
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